Literature DB >> 16837496

Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome.

V V Kaushik, H V Reddy, R C Bucknall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16837496      PMCID： PMC1798243          DOI： 10.1136/ard.2005.047308

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

Authors:  U Specks; F C Fervenza; T J McDonald; M C Hogan
Journal:  Arthritis Rheum       Date:  2001-12

Review 2.  Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?

Authors:  Michael C Sneller
Journal:  Arthritis Rheum       Date:  2005-01

3.  Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

Authors:  R Omdal; K Wildhagen; T Hansen; R Gunnarsson; G Kristoffersen
Journal:  Scand J Rheumatol       Date:  2005 May-Jun       Impact factor: 3.641

4.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

5.  Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.

Authors:  P Eriksson
Journal:  J Intern Med       Date:  2005-06       Impact factor: 8.989
  5 in total
  16 in total

Review 1.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

4.  Churg-Strauss syndrome successfully treated with rituximab.

Authors:  Kristin Kveim Dønvik; Roald Omdal
Journal:  Rheumatol Int       Date:  2009-09-30       Impact factor: 2.631

5.  Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis.

Authors:  Catherine E Najem; Rajwardhan Yadav; Elise Carlson
Journal:  BMJ Case Rep       Date:  2015-05-15

6.  Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.

Authors:  Rodrigo Cartin-Ceba; Karina A Keogh; Ulrich Specks; Sanjeev Sethi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2011-02-16       Impact factor: 5.992

7.  An abdominal presentation of churg-strauss syndrome.

Authors:  J R E Rees; P Burgess
Journal:  Case Rep Med       Date:  2010-08-10

Review 8.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 10.  Small-vessel vasculitis: therapeutic management.

Authors:  Carol A Langford
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.